Lutris Pharma shares gain momentum after reporting that its LUT014 0.1% gel significantly outperformed placebo in Phase 2 trials, achieving a 71.8% success rate in rash severity reduction.
Lutris Pharma's LUT014 0.1% gel has achieved a major clinical milestone, demonstrating a 71.8% treatment success rate compared to 38.5% for the placebo group. This statistically significant result (p=0.003) serves as a critical de-risking event for the company's lead pipeline candidate, validating its efficacy in treating clinician-assessed rash severity.
LUT014 0.1% gel achieved a 71.8% treatment success rate compared to 38.5% for the placebo group.
The study reported a p-value of 0.003, indicating statistically significant improvement.
Lutris Pharma Inc. announced positive Phase 2 clinical data for its LUT014 0.1% gel, showing a 71.8% treatment success rate compared to 38.5% for the placebo group. The study met its primary endpoints with a statistically significant p-value of 0.003, signaling a major clinical de-risking event for the company's lead asset.
The results demonstrate a statistically significant improvement in treating rash severity, with 71.8% of patients achieving success compared to 38.5% in the placebo group, effectively de-risking the drug candidate.